文献速递新生儿儿童消化与营养

新生儿坏死性小肠结肠炎诉讼演变:多年诉讼对未来实践的启示

The Evolving Legal Landscape of Necrotizing Enterocolitis in Neonatology: What Years of Litigation Inform Us About the Future.
PubMed 文献 · J Pediatr · 2026-08-19

该研究回顾分析了美国联邦与州法院涉及牛乳基配方与强化剂相关坏死性小肠结肠炎(NEC)诉讼的公开记录,共识别951起独特诉讼,其中87.2%并入多地区诉讼第3026号。产品责任占86%,医疗过失占12%,其他占2%;2022至2025年间 filing 达898例(94.4%)。两上诉法院对同一法律问题得出相反结论,作者指出裁决并非基于科学证据,NEC诊断仍不精确,牛乳基配方证据存在争议。

要点

  • 共识别951起NEC相关诉讼,87.2%并入MDL No. 3026,产品责任占86%。
  • 2022至2025年 filing 达898例(94.4%),2021年前 filing 率较低。
  • 两上诉法院对配方公司是否须警告父母或医生得出相反结论。

核心结论

  • 两上诉法院对同一法律问题得出相反结论,确认裁决并非基于科学证据。
  • NEC仍是定义不精确的诊断,牛乳基配方与强化剂的证据存在争议。
  • 有记录的知情同意可能无法可靠保护临床医生,潜在不确定性依然存在。

研究设计与样本

  • 采用Westlaw Precision数据进行回顾性描述性分析,检索截至2026年1月的美国联邦与州NEC相关案件。
  • 案件分为A组产品责任、B组医疗过失、C组设备/其他三组,共识别951起独特诉讼。

主要发现

  • 951起诉讼中829起(87.2%)并入多地区诉讼第3026号。
  • 产品责任占86%,医疗过失占12%,其他问题占2%。
  • 2021年前 filing 率较低,2022年后加速,2022至2025年间 filing 898例(94.4%)。

临床怎么用

  • 在科学证据解决争议前,应尽可能平实地向家庭说明牛乳基配方与NEC关系的不确定性。
  • 有记录的知情同意可能无法可靠保护临床医生,需关注法律与沟通风险。

局限性

  • 仅分析公开的联邦与州法院记录,可能未覆盖未公开或未进入诉讼的纠纷。
  • NEC诊断定义不精确且牛乳基配方证据存在争议,限制因果推断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To analyze publicly available federal and state court records involving necrotizing enterocolitis (NEC)-related litigation related to bovine milk-based formulas and fortifiers in the US, examining litigation trends, causes of action, geographic patterns, and case outcomes. STUDY DESIGN: A retrospective descriptive analysis was performed using Westlaw Precision data. Search terms were used to identify NEC-related cases across US federal and state jurisdictions as of January 2026. Cases were classified into 3 groups: group A (product liability), group B (medical Malpractice), and group C (equipment/other). This study characterized the legal landscape and lack of clear scientific data for causal relationship between bovine milk-based fortifiers and formulas and NEC. RESULTS: A total of 951 unique lawsuits were identified. Of these, 829 (87.2%) were consolidated within Multi District Litigation No. 3026. Product liability accounted for 86%, medical malpractice 12% and other issues 2%. Filing rates remained low through 2021, accelerating after 2022, with 898 cases (94.4%) filed between 2022 and 2025. Landmark verdicts included $495 million against Abbott Laboratories, upheld on appeal in May 2026, and $60 million against Mead Johnson, reversed on appeal in June 2026. CONCLUSIONS: Two appellate courts have now reached opposite conclusions on the same legal question, whether a formula company must warn parents or doctors, confirming that these verdicts are not based on scientific evidence. NEC remains an imprecisely defined diagnosis, and the evidence on bovine milk-based formulas is contested. A documented consent may not reliably protect clinicians. The underlying uncertainty remains, no matter what any single court decides. Until scientific evidence resolves this issue, the logical step is to share this uncertainty with families as plainly as possible.

来源:J Pediatr,查看原文。版权归原作者所有。

引用

  1. Singh AP, Holcomb M, Lakshminrusimha S, et al. The Evolving Legal Landscape of Necrotizing Enterocolitis in Neonatology: What Years of Litigation Inform Us About the Future. J Pediatr. 2026. PMID: 42617795. doi:10.1016/j.jpeds.2026.115289

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。